Mercuri, et al.; “Discovery and development of INNA-051, a TLR2/6 agonist for the prevention of complications resulting from viral respiratory infections”; Antiviral Research, 2025 https://doi.org/10.1016/j.antiviral.2024.106063
Mercuri, et al.; “Evaluation of intranasal TLR2/6 agonist INNA-051: safety, tolerability and proof of pharmacology”; ERJ Open Res 2024 https://doi.org/10.1183/23120541.00199-2024
Tal-Singer, et al; “The COPD Foundation’s COPD360Net Initiative Approach to Patient-Centric Drug Development: A Case Study in Using Patient Surveys to Inform New Treatments for Viral Respiratory Infections“; Journal of Patient Experience, 2023 https://doi.org/10.1177/23743735231151554
Deliyannis et al; “TLR2-mediated activation of innate responses in the upper airways confers antiviral protection of the lungs“; JCI Insight, 2021 https://doi.org/10.1172/jci.insight.140267
Girkin et al; “TLR2-mediated innate immune priming boosts lung anti-viral immunity“; European Respiratory Journal, 2020 https://doi.org/10.1183/13993003.01584-2020
Proud et al; “Prophylactic intranasal administration of a TLR2/6 agonist reduces upper respiratory tract viral shedding in a SARS-CoV-2 challenge ferret model“; EBioMedicine, 2020 https://doi.org/10.1016/j.ebiom.2020.103153
Mifsud et al; “Reducing the impact of influenza-associated secondary pneumococcal infections“; Immunol. Cell Biol, 2015 https://doi.org/10.1038/icb.2015.71
Mifsud et al; “Generation of Adaptive Immune Responses Following Influenza Virus Challenge is Not Compromised by Pre-Treatment with the TLR-2 Agonist Pam2Cys“; Front Immunol, 2015 https://doi.org/10.3389/fimmu.2015.00290
Tan et al; “Intranasal administration of the TLR2 agonist Pam2Cys provides rapid protection against influenza in mice“; Mol. Pharm, 2012 https://doi.org/10.1021/mp300257x
